EUVIMEDEUVIMED entdecken
Crossref

Revisiting Stability: The Missing Therapeutic Endpoint in Active Vitiligo Trials

Hitaishi Mehta iD, Muthu Sendhil Kumaran iD, Davinder Parsad iD, Keshavamurthy Vinay iD

Pigment Cell & Melanoma Research · 2026-07 · 39 (4)

DOI: 10.1111/pcmr.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 01.07.2026. Verfasst von Hitaishi Mehta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

biomarkersclinical trialsdisease stabilityimmunosuppressionoutcome measuresvitiligo

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Hitaishi Mehta, Muthu Sendhil Kumaran, Davinder Parsad, Keshavamurthy Vinay

Zitieren

APA

Mehta, H., Kumaran, M. S., Parsad, D., & Vinay, K. (2026). Revisiting Stability: The Missing Therapeutic Endpoint in Active Vitiligo Trials. Pigment Cell & Melanoma Research, 39(4). https://doi.org/10.1111/pcmr.70109

Vancouver

Mehta H, Kumaran MS, Parsad D, Vinay K. Revisiting Stability: The Missing Therapeutic Endpoint in Active Vitiligo Trials. Pigment Cell & Melanoma Research. 2026;39(4). doi:10.1111/pcmr.70109

BibTeX
@article{Mehta2026,
  author = {Mehta, Hitaishi and Kumaran, Muthu Sendhil and Parsad, Davinder and Vinay, Keshavamurthy},
  title = {Revisiting Stability: The Missing Therapeutic Endpoint in Active Vitiligo Trials},
  journal = {Pigment Cell & Melanoma Research},
  year = {2026},
  volume = {39},
  number = {4},
  doi = {10.1111/pcmr.70109}
}
Kostenlos starten →